Implanet Recruits a Sales Director in the United States to Support Its Growth Dynamic

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729), a medical technology company specializing in vertebral and knee-surgery implants, announces, within the framework of its structuring and commercial expansion plan, the appointment of Daniel S. Kirkpatrick as Sales Director for the Eastern United States.

With 20 years of experience in sales management in the field of spine surgery, Daniel S. Kirkpatrick rapidly rose through the ranks at Zimmer Spine in the United States. At Implanet, he will be responsible for managing sales across the Eastern United States, a position he held for more than a decade at Abbot Spine and Zimmer Spine successively.

"The appointment of Daniel S. Kirkpatrick, who I have known personally for many years, as Sales Director for the East of the United States will allow Implanet America to have access to a commercial network specializing in sales of top-of-the-range spine surgery implants, a network Daniel has built and maintained throughout his career”, comments Ludovic Lastennet, CEO of Implanet. "As announced, since January we have seen the arrival of a Sales Director for the West of the country and a Marketing and Training Director, have signed distribution agreements with two new partners and have extended our coverage to four more States. The recruitment of Daniel S. Kirkpatrick is the latest step on this road, and will consolidate our organization on this market in order to accelerate the deployment of the JAZZ sales network and recruit the best-positioned commercial partners.”

Implanet confirms its eligibility for the "PEA-PME” SME equity savings plan

Implanet confirms that it is eligible for the new PEA-PME SME equity savings plan setup whose implementing decree was published in the Journal Officiel (official journal) on 4 March 2014 (decree n°2014-283). This new savings device, which benefits from the same fiscal advantages as the PEA equity savings plan, must consist of at least 75% of SME and VSE securities, including 50% in shares, and has a ceiling of €75,000.

Next financial press release: Q1 2014 revenue, on 28 April 2014

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 35 staff and recorded 2013 sales of €6.7 million.

For further information, please visit www.implanet.com